Business Context and Reporting Period
This Form 8-K Current Report was filed by LIFECORE BIOMEDICAL, INC. on July 15, 2025. The filing discloses the Board of Directors' approval of a cash incentive pay plan for the fiscal year 2026, which ends on May 31, 2026.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current or prior periods. The document focuses exclusively on the structure of executive compensation.
Material Changes
The primary material change reported is the establishment of the 2026 Bonus Plan for executive officers. Key structural elements include:
- Performance Weighting: 80% of the bonus opportunity is tied to Company financial performance (Adjusted EBITDA and development revenue), 10% to individual performance objectives, and 10% to five equally-weighted Company business goals.
- Thresholds: No bonus is earned for a specific financial goal if minimum performance is not met. Crucially, no amounts will be earned under the entire plan unless minimum Adjusted EBITDA is achieved.
- Caps: The maximum cash bonus for financial performance goals is capped at 200% of the target bonus opportunity.
Guidance, Outlook, and Management Commentary
The filing outlines the specific metrics and definitions used for the 2026 fiscal year:
- Adjusted EBITDA Definition: Earnings before interest, taxes, depreciation, and amortization, excluding non-normalized costs such as change in fair value derivatives, financing fees, restructuring costs, and stockholder activist settlement costs. It includes the cost of bonuses under the 2026 Bonus Plan.
- Development Revenue Definition: Revenue from existing or new clinical or commercial programs recognized under U.S. GAAP.
- Executive Target Percentages:
- Paul Josephs (CEO): 100% of annual base salary.
- Ryan D. Lake (CFO): 60% of annual base salary.
- Thomas D. Salus (Chief Legal and Administration Officer): 50% of annual base salary (subject to a 125% multiplier on earned amounts per his employment agreement).
- Clawback Policy: All payments are subject to the Company's Compensation Recoupment Policy adopted on October 2, 2023.
Investor Verification Checklist
- Verify the specific dollar amounts for the "minimum" and "target" Adjusted EBITDA and development revenue goals, as these are not disclosed in this filing.
- Review the Board-approved matrix referenced in the text to understand the exact payout curve for performance above or below target levels.
- Confirm the current annual base salaries of the named executive officers to calculate potential bonus values.
- Examine the Company's Compensation Recoupment Policy to understand the specific conditions triggering a clawback.